AAAAAA
Results: 1-25/41
Authors:
CONNORS JM
Citation: Jm. Connors, CONTROVERSIES AND FUTURE-DIRECTIONS IN THE THERAPY OF LYMPHOMA, Leukemia & lymphoma (Print), 30, 1998, pp. 1-2
Authors:
JAMES GK
HORSMAN D
CONNORS JM
KLASA R
WILSON K
ARGATOFF L
GASCOYNE RD
Citation: Gk. James et al., CLINICOPATHOLOGICAL ANALYSIS OF FOLLICULAR LYMPHOMA WITH A POLYPLOID KARYOTYPE, Leukemia & lymphoma, 28(3-4), 1998, pp. 383-389
Authors:
GASCOYNE RD
WU CD
CHHANABHAI M
MORRIS SW
PULFORD K
MASON D
GREINER TC
CONNORS JM
VOSE JM
COLDMAN A
WEISENBURGER DD
Citation: Rd. Gascoyne et al., PROGNOSTIC-SIGNIFICANCE OF ALK ONCOGENE EXPRESSION IN ANAPLASTIC LARGE-CELL LYMPHOMA (ALCL), Modern pathology, 11(1), 1998, pp. 129-129
Authors:
CONNORS JM
Citation: Jm. Connors, PROBLEMS IN LYMPHOMA MANAGEMENT - SPECIAL SITES OF PRESENTATION, Oncology, 12(2), 1998, pp. 185-191
Authors:
CONNORS JM
SCHUBERT C
SHAPIRO R
Citation: Jm. Connors et al., SYPHILIS OR ABUSE - MAKING THE DIAGNOSIS AND UNDERSTANDING THE IMPLICATIONS, Pediatric emergency care, 14(2), 1998, pp. 139-142
Authors:
CONNORS JM
KRONAUGE JF
CASTRONOVO F
MANNTING F
JONES AG
SIEFF C
ANTIN JH
Citation: Jm. Connors et al., PHARMACOKINETICS AND BIODISTRIBUTION OF IN-111-DTPA-G-CSF IN NONHUMAN-PRIMATES, The Journal of nuclear medicine, 39(5), 1998, pp. 843-843
Authors:
CONNORS JM
SAITOGEE Y
UHL L
MCGURK S
CHURCHILL WH
Citation: Jm. Connors et al., RAPID RESPONSE OF TICLOPIDINE ASSOCIATED TTP TO PLASMAPHERESIS, Transfusion, 38(10), 1998, pp. 249-249
Authors:
AU WY
KLASA RJ
LE N
GASCOYNE RD
CONNORS JM
Citation: Wy. Au et al., SECONDARY MALIGNANCIES IN HAIRY-CELL LEUKEMIA - A 20-YEAR, GEOGRAPHICALLY DEFINED POPULATION-BASED STUDY, British Journal of Haematology, 102(1), 1998, pp. 189-189
Authors:
AU WY
KLASA RJ
GALLAGHER R
LE N
GASCOYNE RD
CONNORS JM
Citation: Wy. Au et al., 2ND MALIGNANCIES IN PATIENTS WITH HAIRY-CELL LEUKEMIA IN BRITISH-COLUMBIA - A 20-YEAR EXPERIENCE, Blood, 92(4), 1998, pp. 1160-1164
Authors:
HOSKINS PJ
LE N
GASCOYNE RD
KLASA R
SHENKIER T
OREILLY S
CONNORS JM
Citation: Pj. Hoskins et al., ADVANCED DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH 12-WEEK COMBINATIONCHEMOTHERAPY - NATURAL-HISTORY OF RELAPSE AFTER INITIAL COMPLETE RESPONSE AND PROGNOSTIC VARIABLES DEFINING OUTCOME AFTER RELAPSE, Annals of oncology, 8(11), 1997, pp. 1125-1132
Authors:
AUER IA
GASCOYNE RD
CONNORS JM
COTTER FE
GREINER TC
SANGER WG
HORSMAN DE
Citation: Ia. Auer et al., T(11-18)(Q21-Q21) IS THE MOST COMMON TRANSLOCATION IN MALT LYMPHOMAS, Annals of oncology, 8(10), 1997, pp. 979-985
Authors:
CONNORS JM
OREILLY SE
Citation: Jm. Connors et Se. Oreilly, TREATMENT CONSIDERATIONS IN THE ELDERLY PATIENT WITH LYMPHOMA, Hematology/oncology clinics of North America, 11(5), 1997, pp. 949
Authors:
OREILLY SE
CONNORS JM
MACPHERSON N
KLASA R
HOSKINS P
Citation: Se. Oreilly et al., MALIGNANT-LYMPHOMAS IN THE ELDERLY, Clinics in geriatric medicine, 13(2), 1997, pp. 251
Authors:
LEE AYY
CONNORS JM
KLIMO P
OREILLY SE
GASCOYNE RD
Citation: Ayy. Lee et al., LATE RELAPSE IN PATIENTS WITH DIFFUSE LARGE-CELL LYMPHOMA TREATED WITH MACOP-B, Journal of clinical oncology, 15(5), 1997, pp. 1745-1753
Authors:
CONNORS JM
KLIMO P
ADAMS G
BURNS BF
COOPER I
MEYER RM
OREILLY SE
PATER J
QUIRT I
SADURA A
SHUSTIK C
SKILLINGS J
SUTCLIFFE S
VERMA S
YOSHIDA S
ZEE B
Citation: Jm. Connors et al., TREATMENT OF ADVANCED HODGKINS-DISEASE WITH CHEMOTHERAPY - COMPARISONOF MOPP ABV HYBRID REGIMEN WITH ALTERNATING COURSES OF MOPP AND ABVD - A REPORT FROM THE NATIONAL-CANCER-INSTITUTE OF CANADA CLINICAL-TRIALS GROUP/, Journal of clinical oncology, 15(4), 1997, pp. 1638-1645
Authors:
AUER I
PULFORD K
MASON DY
STROUD D
CONNORS JM
GASCOYNE RD
Citation: I. Auer et al., PROGNOSTIC-SIGNIFICANCE OF P80 ALK1 EXPRESSION IN DIFFUSE LARGE-CELL LYMPHOMAS(DLCL)/, Laboratory investigation, 76(1), 1997, pp. 695-695
Authors:
CHHANABHAI M
CONNORS JM
GASCOYNE RD
Citation: M. Chhanabhai et al., PROGNOSTIC-SIGNIFICANCE OF THE EXPRESSION OF TOPOISOMERASE-II-ALPHA IN DIFFUSE LARGE-CELL LYMPHOMAS (DLCL), Laboratory investigation, 76(1), 1997, pp. 713-713
Authors:
GASCOYNE RD
AUER I
DUPUIS B
CONNORS JM
Citation: Rd. Gascoyne et al., THE RELATIONSHIP AND PROGNOSTIC-SIGNIFICANCE OF P21 AND P53 EXPRESSION IN DIFFUSE LARGE-CELL LYMPHOMAS (DLCL), Laboratory investigation, 76(1), 1997, pp. 730-730
Authors:
GASCOYNE RD
ARGATOFF L
JAMES G
KLASA R
WILSON K
CONNORS JM
HORSMAN DE
Citation: Rd. Gascoyne et al., THE PROGNOSTIC-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN FOLLICULAR LYMPHOMAS (FL), Laboratory investigation, 76(1), 1997, pp. 731-731
Authors:
GASCOYNE RD
KRAJEWSKA M
KRAJEWSKI S
CONNORS JM
REED JC
Citation: Rd. Gascoyne et al., PROGNOSTIC-SIGNIFICANCE OF BAX PROTEIN EXPRESSION IN DIFFUSE AGGRESSIVE NON-HODGKINS-LYMPHOMA, Blood, 90(8), 1997, pp. 3173-3178
Authors:
CONNORS JM
KRONAUGE J
CASTRONOVO F
MANNTING F
JONES A
SIEFF C
ANTIN JH
Citation: Jm. Connors et al., PHARMACOKINETICS AND BIODISTRIBUTION OF IN-111-DTPA-G-CSF NONHUMAN-PRIMATES, Blood, 90(10), 1997, pp. 3548-3548
Authors:
TOZE CL
SHEPHERD JD
NANTEL SH
KLINGEMANN HG
SUTHERLAND HJ
NEVILL TJ
HOGGE DE
GASCOYNE RD
CONNORS JM
BARNETT MJ
Citation: Cl. Toze et al., ALLOGENEIC BONE-MARROW TRANSPLANTATION (ALLO BMT) FOR LOW-GRADE LYMPHOMA (LGL) AND CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL), Blood, 90(10), 1997, pp. 4513-4513
Authors:
WATSON AL
BARNETT MJ
NANTEL SH
TOZE CL
NEVILL TJ
HOGGE DE
KLINGEMANN HG
SUTHERLAND HJ
CONNORS JM
GASCOYNE RD
SCHULTZ KR
DAVIS JH
NITTA JY
SHEPHERD JD
Citation: Al. Watson et al., TREATMENT OF PROGRESSIVE INTERMEDIATE GRADE NON-HODGKINS-LYMPHOMA WITH INTENSIVE THERAPY AND HEMATOPOIETIC STEM-CELL TRANSPLANTATION, Blood, 90(10), 1997, pp. 4515-4515
Authors:
PORTER DL
COLLINS R
DROBYSKI W
CONNORS JM
VANHOEF M
ANTIN J
Citation: Dl. Porter et al., LONG-TERM FOLLOW-UP OF 55 PATIENTS WHO ACHIEVED COMPLETE REMISSION (CR) AFTER DONOR LEUKOCYTE INFUSIONS (DLI) FOR RELAPSE AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION (BMT), Blood, 90(10), 1997, pp. 2444-2444
Authors:
PORTER DL
CONNORS JM
DOYLE B
MCGARIGLE C
SAIDMAN S
VANDEERLIN V
LEONARD D
ANTIN JH
Citation: Dl. Porter et al., DONOR LEUKOCYTE INFUSIONS (DLI) AS PRIMARY ALLOGENEIC ADOPTIVE IMMUNOTHERAPY FOR PATIENTS WITH MALIGNANCIES, Blood, 90(10), 1997, pp. 2445-2445